In this article, Christian Fortunel, Vice President of LZ Lifescience, discusses today’s most significant market trends, including continuous manufacturing, the increased demand for individualised medicines, patient-centricity and globalisation, as well as FDA’s focus on quality, and addresses the advantages that manufacturing execution systems (MES) bring in meeting the complexities of these developments.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
